Liver Failure and Liver Disease

You have full text access to this OnlineOpen article

Noninvasive measures of liver fibrosis†

  1. Don C. Rockey1,‡,*,
  2. D. Montgomery Bissell2

Article first published online: 30 JAN 2006

DOI: 10.1002/hep.21046

Issue

Hepatology

Hepatology

Special Issue: 25th Anniversary Issue

Volume 43, Issue S1, pages S113–S120, February 2006

Additional Information

How to Cite

Rockey, D. C. and Bissell, D. M. (2006), Noninvasive measures of liver fibrosis. Hepatology, 43: S113–S120. doi: 10.1002/hep.21046

Author Information

  1. 1

    Department of Medicine, and the Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX

  2. 2

    Department of Medicine, and the Division of Gastroenterology and Liver Center, University of California at San Francisco, San Francisco, CA

  1. ‡

    fax:214-648-0274.

*University of Texas Southwestern Medical Center, Department of Internal Medicine, Division of Digestive and Liver Diseases, 5323 Harry Hines Blvd, Dallas, TX 75390-8887

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 30 JAN 2006
  2. Article first published online: 30 JAN 2006

Funded by

  • NIH. Grant Numbers: R01 DK 50574, R01 DK 57830, P30 DK 26743
  • Burroughs Welcome Fund
  • BWF Translational Scientist Award

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (613K)

References

  • 1
    Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin. Liver. Dis 1990; 10: 1–10.
  • 2
    Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepatol 2000; 7: 258–267.
    Direct Link:
  • 3
    Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356–1361.
    Direct Link:
  • 4
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–1231.
  • 5
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.
    Direct Link:
  • 6
    Ludwig J, Batts KP, Moyer TP, Poterucha JJ. Advances in liver biopsy diagnosis. Mayo Clin Proc 1994; 69: 677–678.
  • 7
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289–293.
    Direct Link:
  • 8
    Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241–246.
    Direct Link:
  • 9
    Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257–264.
    Direct Link:
  • 10
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–472.
  • 11
    Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477–481.
    Direct Link:
  • 12
    Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: S185–S194.
    Direct Link:
  • 13
    Arenas JI, Vargas HE. Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterol Clin North Am 2004; 33: 549–562, ix.
  • 14
    Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 95–107.
  • 15
    Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981–985.
  • 16
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–1313.
  • 17
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–816.
  • 18
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800–807.
  • 19
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971–975.
    Direct Link:
  • 20
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614–2618.
    Direct Link:
  • 21
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898–1906.
  • 22
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832.
  • 23
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054–1058.
    Direct Link:
  • 24
    Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828–833.
    Direct Link:
  • 25
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47–S56.
    Direct Link:
  • 26
    Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38: 481–492.
    Direct Link:
  • 27
    Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376–1382.
    Direct Link:
  • 28
    Chalasani N, Imperiale TF, Ismail A, Sood G, Carey M, Wilcox CM, et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol 1999; 94: 3285–3291.
    Direct Link:
  • 29
    Zaman A, Becker T, Lapidus J, Benner K. Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med 2001; 161: 2564–2570.
  • 30
    D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475–505.
  • 31
    Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000; 15: 386–390.
    Direct Link:
  • 32
    Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218–224.
  • 33
    Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44–48.
    Direct Link:
  • 34
    Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986–992.
  • 35
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–526.
    Direct Link:
  • 36
    Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39: 1239–1247.
    Direct Link:
  • 37
    Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342: 895–898.
  • 38
    Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis: diagnostic interest. Dig Dis Sci 1994; 39: 2426–2432.
  • 39
    Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069–1075.
  • 40
    Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003; 49: 450–454.
  • 41
    Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
  • 42
    Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222–230.
  • 43
    Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167–174.
  • 44
    Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005; 39: S158–S161.
  • 45
    Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48–54.
    Direct Link:
  • 46
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–350.
  • 47
    Adler M, Verset D, Bouhdid H, Bourgeois N, Gulbis B, Le Moine O, et al. Prognostic evaluation of patients with parenchymal cirrhosis: proposal of a new simple score. J Hepatol 1997; 26: 642–649.
  • 48
    Giannini EG, Testa R. 13C-breath tests and liver fibrosis. Eur Rev Med Pharmacol Sci 2004; 8: 51–54.
  • 49
    Giannini EG, Fasoli A, Borro P, Botta F, Malfatti F, Fumagalli A, et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 279–285.
  • 50
    Testa R, Caglieris S, Risso D, Arzani L, Campo N, Alvarez S, et al. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. Am J Gastroenterol 1997; 92: 2268–2273.
  • 51
    Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935–942.
  • 52
    Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704–1713.
  • 53
    Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005; 51: 328–335.
  • 54
    Bora R, Ratziu V, Bedossa P, Munteanu M, Poynard T. Diagnostic value of biochemical markers, fibrotest-actitest-HCV-fibrosure compared with serum protein profiling by seldi-TOF, for the diagnosis of bridging fibrosis in patients with chronic hepatitis C. Hepatology 2004; 40: 517A.
  • 55
    Dev A, White I, Symonds W, Patel K, Griffin P, Tsokanas N, et al. A serum proteomic analysis in hepatitis C fibrosis. J Hepatol 2005; 42( Suppl 2): 117A.
  • 56
    Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429–434.
  • 57
    Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005; 307: 538–544.
  • 58
    Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 2005; 23: 313–320.
View Full Article (HTML) Get PDF (613K)